Top Story

There's still time to save on ESMO 2014 congress registration fees! Late registration deadline: 20 August


E. van Cutsem comments two studies: NAPOLI-1, demonstrating improved survival for met pancreatic cancer patients with the novel drug MM-398; the SPARC analysis of MPACT, showing that the protein cannot be used as predictive marker for gemcitabine + nab-paclitaxel. There is still an unmet need to identify predictive markers for these patients.